Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626228 | 0.89 | BTK (0.47) | BTKKITJAK1JAK2ACHE | |
| SCHEMBL14798056 | 0.89 | BTK (0.47) | BTKKITJAK1JAK2ACHE | |
| SCHEMBL20480851 | 0.87 | GPR119 (0.42) | BTKKCNH2KITJAK1JAK2 | |
| SCHEMBL15143899 | 0.86 | BTK (0.57) | BTKJAK1JAK2GPR119STS | |
| SCHEMBL15710701 | 0.86 | BTK (0.57) | BTKJAK1JAK2GPR119STS | |
| SCHEMBL16320728 | 0.85 | BTK (0.51) | BTKJAK1JAK2JAK3 | |
| SCHEMBL16320727 | 0.85 | BTK (0.51) | BTKJAK1JAK2JAK3 | |
| SCHEMBL30760813 | 0.83 | JAK2 (0.41) | BTKKCNH2KITJAK1JAK2 | |
| SCHEMBL30760880 | 0.83 | JAK2 (0.41) | BTKKCNH2KITJAK1JAK2 | |
| SCHEMBL30760937 | 0.80 | JAK2 (0.45) | BTKJAK1JAK2ACHEJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10314844-B2 | Inhibitors of Bruton's tyrosine kinase | GILEAD SCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180243311-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | GILEAD SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314844-B2 | Inhibitors of Bruton's tyrosine kinase | BTK, ABL1, LYN | BTK 1/4885KCNH2 3048/4885KIT 648/4885 |
| US-20180243311-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, ABL1, LYN | BTK 1/4885KCNH2 3048/4885KIT 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.